Lutetium-177 (177Lu)-PSMA is a radiolabeled small molecule that binds with high affinity to PSMA, enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer, with promising results in this tumor type (106). This evidence concerns the gene FOLH1 and prostate carcinoma.